Autolus Therapeutics (NASDAQ:AUTL) Shares Up 5.2% - Still a Buy?

Key Points

• Autolus Therapeutics shares rose 5.2%, trading at $1.94 with a significant drop in trading volume to 799,498 shares.
• Wells Fargo lowered its price target for the stock from $6.00 to $5.00, while Needham set a higher target of $10.00; the consensus price target is currently $9.12.
• The company recently reported a quarterly earnings per share of -$0.18, surpassing expectations of -$0.24 and generating $13.5 million in revenue.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) shot up 5.2% on Thursday . The company traded as high as $1.98 and last traded at $1.94. 799,498 shares were traded during trading, a decline of 55% from the average session volume of 1,788,382 shares. The stock had previously closed at $1.84.

Analysts Set New Price Targets

A number of brokerages recently weighed in on AUTL. Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, July 21st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $9.12.

Autolus Therapeutics Trading Up 6.3%

The stock has a 50 day simple moving average of $2.34 and a 200 day simple moving average of $1.90. The firm has a market capitalization of $520.30 million, a PE ratio of -2.32 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business had revenue of $13.50 million for the quarter, compared to analysts' expectations of $12.92 million. As a group, equities analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in Autolus Therapeutics in the fourth quarter worth $26,000. Barclays PLC grew its stake in Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares during the period. R Squared Ltd purchased a new stake in Autolus Therapeutics in the second quarter worth $50,000. Invesco Ltd. grew its stake in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares during the period. Finally, Delaney Dennis R purchased a new stake in Autolus Therapeutics in the second quarter worth $55,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.